Skip to main content
BCAX
NASDAQ Life Sciences

Bicara Therapeutics 公布 Q4 净亏损 3740 万美元，确认启动 3 期试验

feedReported by Reuters
Sentiment info
Neutral
Importance info
7
Price
$19.51
Mkt Cap
$1.164B
52W Low
$7.8
52W High
$20.25
Market data snapshot near publication time

summarizeSummary

Bicara Therapeutics 公布其第四季度净亏损为 3740 万美元，以及 2025 年全年净亏损为 1.38 亿美元。这份财务更新提供了对公司运营表现和现金流耗费的关键见解。报告还重申了其关键的 3 期 FORTIFI-HN01 试验的启动，预计中期分析将于 2027 年中期进行，这是一个之前宣布的重要临床里程碑。虽然 3 期试验的进展对于一家临床阶段生物技术公司来说是一个积极的发展，但财务结果提供了对公司当前财务健康的全面视图。投资者将密切关注未来的财务报告，以获取有关现金储备和试验下一次数据公布进展的更新。

在该公告发布时，BCAX的交易价格为$19.51，交易所为NASDAQ，所属行业为Life Sciences，市值约为$11.6亿。 52周交易区间为$7.80至$20.25。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed BCAX - Latest Insights

BCAX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
8
Bicara Therapeutics Reports Increased Losses Amid Pivotal Phase 3 Trial Advancement and Strong Cash Runway
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:59 AM EDT
Source: Reuters
Importance Score:
7
Bicara Therapeutics Reports Q4 Net Loss of $37.4M, Confirms Phase 3 Trial Initiation
Sentiment: Neutral
View Wiseek Article
BCAX
Mar 30, 2026, 7:47 AM EDT
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Initiates Pivotal Phase 3 Trial and Secures $161.8M in Oversubscribed Offering, Extending Cash Runway to 2029
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Bicara Therapeutics Kicks Off Phase 3 Trial for FORTIFI-HN01, Targeting Year-End Enrollment
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:25 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
RA Capital Management Invests $40M in Bicara Therapeutics Public Offering, Boosting Stake to 11.5%
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:22 PM EST
Filing Type: 4
Importance Score:
8
RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants
Sentiment: Positive
View Wiseek Article
BCAX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Bicara Therapeutics Closes $161.8M Public Offering, Bolstering Cash for Drug Development
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 25, 2026, 9:50 PM EST
Filing Type: 424B5
Importance Score:
8
Bicara Therapeutics Finalizes $150M Public Offering of Common Stock and Warrants at Discount
Sentiment: Negative
View Wiseek Article
BCAX
Feb 24, 2026, 9:47 PM EST
Filing Type: FWP
Importance Score:
8
Bicara Therapeutics Amends Public Offering to Include Pre-Funded Warrants for $150M Capital Raise
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
7
Bicara Therapeutics Announces $150M Public Offering to Fund Pipeline Advancement
Sentiment: Neutral
View Wiseek Article